Grace Therapeutics, Inc.
GTx-101
Postherpetic Neuralgia
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for GTx-101 in Postherpetic Neuralgia are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Completed Phase 1 (single dose) in 2022 Met all primary outcome measures”